Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Giving more than one
drug (combination chemotherapy) may kill more cancer cells. A donor stem cell transplant may
replace the patient's immune cells and help destroy any remaining cancer cells
(graft-versus-tumor effect). Giving combination chemotherapy before the transplant helps stop
the growth of cancer cells and stop the patient's immune system from rejecting the donor's
stem cells. It is not yet known which combination chemotherapy regimen is more effective in
treating young patients with acute lymphoblastic leukemia.
PURPOSE: This randomized phase III trial is studying different risk-adjusted combination
chemotherapy regimens in treating young patients with acute lymphoblastic leukemia.